Eris Lifesciences Ltd (BOM:540596)
₹ 1353.8 11.3 (0.84%) Market Cap: 184.29 Bil Enterprise Value: 213.23 Bil PE Ratio: 52.93 PB Ratio: 6.65 GF Score: 93/100

Q2 2020 Eris Lifesciences Ltd Earnings Call Transcript

Nov 07, 2019 / 11:00AM GMT
Release Date Price: ₹425.6 (+4.47%)
Operator

Ladies and gentlemen, good day, and welcome to the Eris Lifesciences Q2 FY '20 Results Conference Call. (Operator Instructions)

Please note that this conference is being recorded. I now hand the conference over to Mr. Amit Bakshi, Managing Director. Thank you, and over to you.

Amit Indubhushan Bakshi
Eris Lifesciences Limited - Chairman & MD

Hello. I welcome everyone and thank you for joining for this call.

Let me begin by taking you through the presentation that we uploaded and then we can open for Q&A.

So far the quarter, we've grown by 9.4% versus -- what IPM, stood at 11.5% growth. In our Chronic and Sub Chronic therapy, which comprises around 86% of our business, we have grown 11.4% versus 10.6% for the IPM.

On -- we've also shared the secondary numbers for H1 '20, where the trend continues of Eris outperforming IPM in chronic, sub chronic segments. We also continue to have high ranks among our key specialties, fourth with cardiologists, third with diabetologists, gastroenterologists as well as neurologists.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot